The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Deleterious effect of baseline steroids on efficacy of PD-(L)1 blockade in patients with NSCLC.
 
Kathryn Cecilia Arbour
No Relationships to Disclose
 
Laura Mezquita
No Relationships to Disclose
 
Niamh Long
No Relationships to Disclose
 
Hira Rizvi
No Relationships to Disclose
 
Edouard Auclin
No Relationships to Disclose
 
Ai Ni
No Relationships to Disclose
 
Gala Martinez Bernal
Employment - Amgen; Janssen
Honoraria - Amgen; Janssen
Speakers' Bureau - Amgen; Janssen
 
Jamie E. Chaft
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech/Roche; Merck
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst)
 
Roberto Ferrara
No Relationships to Disclose
 
Wei-Chu Victoria Lai
No Relationships to Disclose
 
Lizza Hendriks
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb
Research Funding - Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Roche
 
Joshua K. Sabari
No Relationships to Disclose
 
Caroline Caramella
Consulting or Advisory Role - Bristol-Myers Squibb; Pfizer
 
Andrew J. Plodkowski
No Relationships to Disclose
 
Darragh Halpenny
No Relationships to Disclose
 
David Planchard
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; MSD Oncology; Novartis; Pfizer; Roche
 
Gregory J. Riely
Consulting or Advisory Role - Genentech
Research Funding - ARIAD (Inst); GlaxoSmithKline (Inst); Infinity Pharmaceuticals (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Patent application submitted covering pulsatile use of erlotinib to treat or prevent brain metastases (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Benjamin Besse
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Inivata (Inst); Lilly (Inst); Loxo (Inst); Novartis (Inst); OncoMed (Inst); Onxeo (Inst); ose pharma (Inst); ose pharma (Inst); Pfizer (Inst); Roche/Genentech (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Medarex; Novartis; Pfizer; Pierre Fabre; Roche
 
Matthew David Hellmann
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech; Janssen; Merck; Novartis
Research Funding - Bristol-Myers Squibb